BACKGROUND: ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus. This Phase II, randomized, double-blind, placebo-controlled, multicenter study assessed the immunogenicity, viremia, and safety of the ChimeriVax-WN02 vaccine. METHODS: The 2-part study included adults in general good health. In part 1, subjects aged 18-40 years were randomized to 1 of 4 treatment groups: ChimeriVax-WN02 3.7- × -10(5) plaque-forming units (PFU), 3.7 × 10(4) PFU, 3.7 × 10(3) PFU, or placebo. In part 2, subjects aged 41-64 and ≥ 65 years were randomized to receive ChimeriVax-WN02 3.7 × 10(5) PFU or placebo. RESULTS: In both part 1 and part 2, seroconversion was achieved at day 28 by >96% of subjects in active treatment groups. In part 1, neutralizing antibody titers at day 28 were higher and viremia levels lower with the highest dose, whereas the adverse event profile was similar between the dose groups. In part 2, antibody titers and viremia levels were higher in subjects aged ≥ 65 years, and more subjects in the 41-64 years cohort experienced adverse events. CONCLUSIONS: The ChimeriVax-WN02 vaccine was highly immunogenic in younger adults and the elderly, and it was well tolerated at all dose levels and in all age groups investigated. Clinical Trials.gov identifier: NCT00442169.
RCT Entities:
BACKGROUND: ChimeriVax-WN02 is a live, attenuated chimeric vaccine for protection against West Nile virus. This Phase II, randomized, double-blind, placebo-controlled, multicenter study assessed the immunogenicity, viremia, and safety of the ChimeriVax-WN02 vaccine. METHODS: The 2-part study included adults in general good health. In part 1, subjects aged 18-40 years were randomized to 1 of 4 treatment groups: ChimeriVax-WN02 3.7- × -10(5) plaque-forming units (PFU), 3.7 × 10(4) PFU, 3.7 × 10(3) PFU, or placebo. In part 2, subjects aged 41-64 and ≥ 65 years were randomized to receive ChimeriVax-WN02 3.7 × 10(5) PFU or placebo. RESULTS: In both part 1 and part 2, seroconversion was achieved at day 28 by >96% of subjects in active treatment groups. In part 1, neutralizing antibody titers at day 28 were higher and viremia levels lower with the highest dose, whereas the adverse event profile was similar between the dose groups. In part 2, antibody titers and viremia levels were higher in subjects aged ≥ 65 years, and more subjects in the 41-64 years cohort experienced adverse events. CONCLUSIONS: The ChimeriVax-WN02 vaccine was highly immunogenic in younger adults and the elderly, and it was well tolerated at all dose levels and in all age groups investigated. Clinical Trials.gov identifier: NCT00442169.
Authors: T P Monath; I Levenbook; K Soike; Z X Zhang; M Ratterree; K Draper; A D Barrett; R Nichols; R Weltzin; J Arroyo; F Guirakhoo Journal: J Virol Date: 2000-02 Impact factor: 5.103
Authors: D Nash; F Mostashari; A Fine; J Miller; D O'Leary; K Murray; A Huang; A Rosenberg; A Greenberg; M Sherman; S Wong; M Layton Journal: N Engl J Med Date: 2001-06-14 Impact factor: 91.245
Authors: R S Lanciotti; J T Roehrig; V Deubel; J Smith; M Parker; K Steele; B Crise; K E Volpe; M B Crabtree; J H Scherret; R A Hall; J S MacKenzie; C B Cropp; B Panigrahy; E Ostlund; B Schmitt; M Malkinson; C Banet; J Weissman; N Komar; H M Savage; W Stone; T McNamara; D J Gubler Journal: Science Date: 1999-12-17 Impact factor: 47.728
Authors: B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning Journal: J Virol Date: 2001-05 Impact factor: 5.103
Authors: Julie E Martin; Theodore C Pierson; Sarah Hubka; Steve Rucker; Ingelise J Gordon; Mary E Enama; Charla A Andrews; Qing Xu; Brent S Davis; Martha Nason; Michael Fay; Richard A Koup; Mario Roederer; Robert T Bailer; Phillip L Gomez; John R Mascola; Gwong-Jen J Chang; Gary J Nabel; Barney S Graham Journal: J Infect Dis Date: 2007-12-15 Impact factor: 5.226
Authors: Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond Journal: J Virol Date: 2012-12-05 Impact factor: 5.103
Authors: Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey Journal: J Virol Date: 2013-07-17 Impact factor: 5.103